Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Centessa Pharmaceuticals plc ADR shares valued at $60,750,000 were purchased by Saurabh Saha on Jan 02 ’26. At $24.30 per share, Saurabh Saha acquired 2,500,000 shares.
Also, Accardi Mario Alberto sold 10,000 shares, netting a total of over 288,289 in proceeds. Following the sale of shares at $28.83 each, the insider now holds 178,801 shares.
Before that, Accardi Mario Alberto had added 10,000 shares to its account. In a trade valued at $293,000, the Officer bought Centessa Pharmaceuticals plc ADR shares for $29.30 each.
Analysts at Stephens started covering the stock with ‘”an Overweight”‘ outlook in a report released in late October. As of September 03, 2025, Wells Fargo has initiated its “an Overweight” rating for CNTA.
Analyzing CNTA Stock Performance
On last trading session, Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] rose 1.40% to $22.4. The stock’s lowest price that day was $21.94, but it reached a high of $22.82 in the same session. During the last five days, there has been a surge of approximately 1.59%. Over the course of the year, Centessa Pharmaceuticals plc ADR shares have jumped approximately 50.94%.
Support And Resistance Levels for Centessa Pharmaceuticals plc ADR (CNTA)
RSI (Relative Strength Index) is 34.40 on the 14-day chart, showing neutral technical sentiment.
Is Centessa Pharmaceuticals plc ADR subject to short interest?
Stocks of Centessa Pharmaceuticals plc ADR saw a sharp rise in short interest on 2025-12-31 jumping by 0.17 million shares to 6.25 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 6.08 million shares. A jump of 2.71% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.12 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.12.
Which companies own the most shares of Centessa Pharmaceuticals plc ADR (CNTA)?
In terms of Centessa Pharmaceuticals plc ADR share price expectations, FactSet research, analysts set an average price target of 35 in the next 12 months, up nearly 58.44% from the previous closing price of $22.09. Analysts anticipate Centessa Pharmaceuticals plc ADR stock to reach 42 by 2026, with the lowest price target being 31. In spite of this, 6 analysts ranked Centessa Pharmaceuticals plc ADR stock as Buy at the end of 2026. On July 21, 2025, Truist assigned a price target of “a Buy” to the stock and initiated coverage with a $30.
